Table 7. Meta-analysis of the studies performed in small cell lung cancer, with their characteristics.
|
Group of SCLC (n=4) | |||||||
|---|---|---|---|---|---|---|---|
| Study | Method | Threshold | QS (%) | N Pts | Bcl-2+ (%) | HR | 95% CI |
| Dingemans et al (1999) | IHC-clone 100 | >10 | 67 | 91 | 78 | 1.55 | 0.93–2.58 |
| Kaiser et al (1996) | IHC | >50 | 63 | 146 | 75 | 0.76 | 0.55–1.04 |
| Maitra et al (1999) | IHC-clone 100 | >10 | 46 | 42 | 57 | 0.68 | 0.36–1.27 |
| Takayama et al (1996) | IHC-clone 124 | >10 | 55 | 38 | 55 | 1.31 | 0.64–2.70 |
| Overall (fixed-effects model) | 317 | 71 | 0.92 | 0.73–1.16 | |||
| Overall (random-effects model) | 0.99 | 0.66–1.48 | |||||
| χ2 statistic for heterogeneity=7.35, 3 df, P=0.06 | |||||||
The meaning of the symbols is described in Table 3. IHC=Immunohistochemistry with other antibodies than clone 100 and 124.